Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Study of Volanesorsen in Pediatric and Adolescent Familial Chylomicronemia Syndrome
2020-002997-28Phase 3
- Sponsor
- Akcea Therapeutics, Inc.
- Start
- Jan 2021
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of volanesorsen in primary chylomicronemia (FCS), sponsored by Akcea Therapeutics, Inc. Primary endpoint: Primary efficacy endpoints.
02
Drugs
volanesorsen
03
Conditions
primary chylomicronemia (FCS)
Beyond the preview
Go deeper on 2020-002997-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002997-28.